Opaleye Management Inc. Acquires 11,715 Shares of Harrow Health, Inc. (NASDAQ:HROW) Stock

Harrow Health, Inc. (NASDAQ:HROW) major shareholder Opaleye Management Inc. acquired 11,715 shares of the company’s stock in a transaction that occurred on Tuesday, April 23rd. The stock was acquired at an average price of $10.29 per share, with a total value of $120,547.35. Following the acquisition, the insider now owns 3,786,715 shares in the company, valued at $38,965,297.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

• On Thursday, April 25th, Opaleye Management Inc. acquired 20,000 shares of Harrow Health stock. The stock was acquired at an average price of $9.97 per share, with a total value of $199,400.00.
• On Friday, April 19th, Opaleye Management Inc. acquired 29,400 shares of Harrow Health stock. The stock was acquired at an average price of $10.56 per share, with a total value of $310,464.00.
• On Thursday, March 28th, Opaleye Management Inc. acquired 50,000 shares of Harrow Health stock. The stock was acquired at an average price of $12.82 per share, with a total value of $641,000.00.
• On Wednesday, March 20th, Opaleye Management Inc. purchased 50,600 shares of Harrow Health stock. The shares were purchased at an average price of $9.65 per share, with a total value of $488,290.00.

Harrow Health Stock Down 2.6 %

Harrow Health stock opened at $10.00 on Friday. The firm has a market cap of $353.63 million, a price-to-earnings ratio of -13.33 and a beta of 0.48. Harrow Health, Inc. has a 52-week low of $7.60 and a 52-week high of $28.25. The company has a debt-to-equity ratio of 2.60, a quick ratio of 2.61 and a current ratio of 2.83. The firm has a 50 day moving average price of $11.53 and a two-hundred day moving average price of $11.25.

Harrow Health (NASDAQ:HROW) last announced its quarterly earnings data on Tuesday, March 19th. The company reported ($0.27) EPS for the quarter. The company had revenue of $36.36 million for the quarter, compared to analyst estimates of $37.65 million. Harrow Health had a negative return on equity of 29.48% and a negative net margin of 18.75%. Equities analysts predict that Harrow Health, Inc. will post -0.39 EPS for the current year.

Institutional Trading of Harrow Health

Several large investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC acquired a new stake in shares of Harrow Health during the 3rd quarter worth approximately $26,000. Equitable Trust Co. grew its position in Harrow Health by 2.9% in the 1st quarter. Equitable Trust Co. now owns 83,500 shares of the company’s stock valued at $1,105,000 after purchasing an additional 2,345 shares during the period. Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in Harrow Health in the 3rd quarter valued at $34,000. China Universal Asset Management Co. Ltd. grew its position in Harrow Health by 347.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,063 shares of the company’s stock valued at $46,000 after purchasing an additional 3,155 shares during the period. Finally, Swiss National Bank grew its position in Harrow Health by 5.5% in the 3rd quarter. Swiss National Bank now owns 65,400 shares of the company’s stock valued at $940,000 after purchasing an additional 3,400 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on HROW shares. B. Riley lowered their price target on shares of Harrow Health from $30.00 to $26.00 and set a “buy” rating for the company in a report on Friday, March 22nd. Craig Hallum started coverage on shares of Harrow Health in a report on Thursday, April 11th. They set a “buy” rating and a $24.00 price target for the company.

About Harrow Health

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.